Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Neovasc Inc. T.NVC


Primary Symbol: NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Comment by Barewoodon Mar 21, 2018 9:45pm
140 Views
Post# 27758175

RE:RE:RE:Recent Trading Activity & No response from NVCN??

RE:RE:RE:Recent Trading Activity & No response from NVCN??I doubt that is the case. The downturn corresponds with the copyright infringement litigation. Once the sell off began, it essentially snowballed or panic selling what ever you want to call it. If you read through the NR's you'll make sense of what is happening. Neovasc has since settled its issues, but is now poised for Corporate restructuring. If you listen to the Q&A at the end of the Feb 14

LEERINK Partners 7th Annual Global Healthcare Conference, you will hear our new CEO Fred Colen discuss this turn around. Looking at the charts I note that this downturn began early March 2015 with a few upswings, but the trend has been bearish to this point. No where else to go but up. New management generating revenue and administrative approvals in the U.S. and Europe. Products have already been implanted with little to no complications. Stock is extremely undervalued. 

<< Previous
Bullboard Posts
Next >>